Subscribe to this column
Edward P. Balaban, FACP, DO, FASCO
Edward P. Balaban, DO, FACP, FASCO, is the medical director for the Cancer Care Partnership with Penn State University Cancer Institute and professor of medicine at Penn State Hershey Cancer Institute. He has served as a Practice Guideline Implementation Network (PGIN) representative for Weight-Based Dosing Chemotherapy for Cancer Patients and Gastrointestinal Guideline Advisory Groups. Dr. Balaban is past president of the Pennsylvania Society of Oncology and Hematology. He serves as an ASCO delegate to the American Medical Association House of Delegates (AMA HOD).
Jun 20, 2019
Key cancer-related topics discussed at the AMA-HOD meeting included alcohol ingestion as a causation risk factor, appropriate guidelines for opioids in the cancer setting, and the use of de-identified patient information.
Nov 19, 2018
At a recent meeting, the ASCO delegation to the AMA House of Delegates presented concerns focused on the Competitive Acquisition Program (CAP), among a variety of other issues.
Jun 22, 2018
At the most recent meeting, ASCO's delegation to the AMA House of Delegates were involved in resolutions related to Pharmacy Benefit Managers, opioids, billing for survivorship care plans, alcohol as a modifiable risk for cancer, and more.
Nov 20, 2017
The ASCO delegation was very busy at the American Medical Association House of Delegates recent interim meeting.
Jun 29, 2017
The most recent meeting of the AMA House of Delegates was a particularly important one for oncologists and cancer-related issues.
Nov 28, 2016
We (the ASCO delegation) have just returned from the interim American Medical Association (AMA) House of Delegates meeting in Orlando. ASCO proposed a resolution focused on the restrictive opioid policies being adopted by many states. Many of the state legislations include language restricting...
Latest Blogs